Pherecydes Pharma Société anonyme (ALPHE.PA)

2.425 €

-0.03 (-1.22%)
Rating:
Recommendation:
-
Symbol ALPHE.PA
Price 2.425 €
Beta 0.000
Volume Avg. 0.01M
Market Cap 17.445M
Shares () -
52 Week Range 2.0-8.0
1y Target Est -
DCF Unlevered ALPHE.PA DCF ->
DCF Levered ALPHE.PA LDCF ->
ROE -
ROA -
Operating Margin -
Debt / Equity 64.35% Buy
P/E -
P/B -
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Healthcare
Biotechnology
Paris

Pherecydes Pharma SA develops antibacterial treatments based on the use of bacteriophage viruses or phages. It develops a portfolio of therapeutics, such as anti-Staphylococcus aureusphages for the treatment of bone/joint and diabetic foot ulcer infections; anti-Pseudomonas aeruginosa phages for the treatment of complicated urinary tract infections; and anti-Escherichia coli phages for the treatment of respiratory tract infections. The company was founded in 2006 and is based in Romainville, France.